SEATTLE GENETICS INC's ticker is SGENXXXX and the CUSIP is 812578102. A total of 203 filers reported holding SEATTLE GENETICS INC in Q1 2015. The put-call ratio across all filers is 2.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $90,000 | -12.6% | 789 | -47.4% | 0.01% | -10.0% |
| Q2 2019 | $103,000 | -38.3% | 1,500 | -34.5% | 0.01% | -37.5% |
| Q1 2019 | $167,000 | +943.8% | 2,289 | +663.0% | 0.02% | +700.0% |
| Q4 2018 | $16,000 | -88.9% | 300 | -88.7% | 0.00% | -85.7% |
| Q3 2017 | $144,000 | +128.6% | 2,654 | +116.5% | 0.01% | +133.3% |
| Q2 2017 | $63,000 | +14.5% | 1,226 | +16.9% | 0.01% | 0.0% |
| Q4 2016 | $55,000 | +816.7% | 1,049 | +836.6% | 0.01% | +500.0% |
| Q3 2016 | $6,000 | -94.9% | 112 | -96.4% | 0.00% | -95.2% |
| Q3 2015 | $118,000 | -10.6% | 3,082 | -17.5% | 0.02% | -36.4% |
| Q1 2015 | $132,000 | -10.8% | 3,737 | -19.0% | 0.03% | -29.8% |
| Q4 2014 | $148,000 | +516.7% | 4,616 | +611.2% | 0.05% | +1466.7% |
| Q3 2014 | $24,000 | -51.0% | 649 | -50.1% | 0.00% | -62.5% |
| Q2 2014 | $49,000 | +81.5% | 1,300 | +116.7% | 0.01% | +33.3% |
| Q1 2014 | $27,000 | – | 600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 51,049,760 | $3,738,884,000 | 23.93% |
| Lagoda Investment Management, L.P. | 76,873 | $5,630,000 | 7.16% |
| Matrix Capital Management Company, LP | 3,141,852 | $230,109,000 | 6.14% |
| DOMINI IMPACT INVESTMENTS LLC | 3,120 | $229,000 | 3.51% |
| Opus Point Partners Management, LLC | 17,832 | $1,306,000 | 1.77% |
| Capital International Sarl | 188,200 | $13,784,000 | 1.72% |
| EMORY UNIVERSITY | 33,368 | $2,444,000 | 1.72% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 60,900 | $4,460,000 | 1.65% |
| CAPITAL GUARDIAN TRUST CO | 1,358,254 | $99,415,000 | 1.32% |
| Rhenman & Partners Asset Management AB | 150,598 | $11,030,000 | 1.29% |